Sandu Pharmaceuticals Reports Positive Financial Results for Q2 FY25

Nov 16 2024 05:16 PM IST
share
Share Via
Sandu Pharmaceuticals, a microcap trading company, has reported its financial results for the quarter ending September 2024. Despite a 'Strong Sell' rating by MarketsMojo, the company's overall score has improved from 0 to 5 in the last three months. Net sales, operating profit, and profit before tax have all seen an increase, indicating a positive trend in the near term. However, this is not a recommendation for investment and investors should conduct their own research before making any decisions.

Sandu Pharmaceuticals, a microcap trading company, has recently announced its financial results for the quarter ending September 2024. The company’s stock has been given a ‘Strong Sell’ rating by MarketsMOJO.

According to the financial report, Sandu Pharma. has shown a flat performance in the second quarter of the fiscal year 2024-25. However, there has been a significant improvement in the company’s overall score, which has increased from 0 to 5 in the last three months.


The company’s net sales for the quarter were at its highest in the last five quarters, reaching Rs 17.70 crore. This indicates a positive trend in the near term for sales. Similarly, the operating profit (PBDIT) for the quarter was also at its highest in the last five quarters, at Rs 0.90 crore. The operating profit margin has also seen an improvement, reaching its highest at 5.08%. This shows an increase in the company’s efficiency.


Furthermore, the profit before tax less other income (PBT) for the quarter was at its highest in the last five quarters, at Rs 0.71 crore. The near term trend for PBT is also positive. In the nine-month period, the company’s profit after tax (PAT) was higher at Rs 1.26 crore compared to the previous 12-month period ending in September 2024, which was at Rs 1.14 crore. This indicates a strong performance by the company in the first nine months of the fiscal year.


Overall, Sandu Pharmaceuticals has shown a positive trend in its financial performance for the quarter ending September 2024. However, it is important to note that this is not a recommendation for investment and is based solely on the facts provided by the company’s financial report. Investors are advised to do their own research and analysis before making any investment decisions.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News